Reported 3 days ago
ImmunityBio, Inc. (NASDAQ:IBRX) reported a remarkable 60% revenue increase in Q2 2025, fueled by the growing adoption of its FDA-approved immunotherapy ANKTIVA for bladder cancer. The company's revenue reached $26.4 million, driven by the recent commercialization boost following regulatory approvals, including in the UK. ANKTIVA addresses a significant gap in cancer treatments and aims to decrease the need for invasive procedures. This growth follows an $80 million capital raise to support ongoing development.
Source: YAHOO